Login to Your Account

Financings Roundup

Lumena Large: $23M Series A Funds Phase II Cholestatic Bid

By Randy Osborne
Staff Writer

Thursday, May 9, 2013

With Phase II trials on the runway for several forms of adult and pediatric cholestatic liver disease, a rare condition for which no therapy exists, Lumena raised $23 million in a Series A financing that is expected to get the company through those studies, after which the firm will deliberate the matter of whether to bring aboard a partner in the rare-disease effort.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription